SecBot SecBot
8-K ·Filed Feb 24, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago SEC0001649094-26-000005
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming clinical data readouts: topline data from OPUS-1 expected in Q4 2026, and OPUS-2/OPUS-3 data expected in first half of 2027. The strong cash position provides runway for clinical development, but continued losses are expected until potential commercialization.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$63.04
T+0 close · Feb 24, 2026 · via day close
Latest settled
−25.17%
T+60 · $47.17
Vs SPY
−32.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $63.04entry
  2. T+1 · 9mo ago −4.82%α −4.28% · $60.00
  3. T+5 · 9mo ago −4.62%α −3.52% · $60.13
  4. T+20 · 8mo ago −11.31%α −6.07% · $55.91
  5. T+60 · 6mo ago −25.17%α −32.13% · $47.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to a larger net loss, while maintaining a strong cash position of $2.44 billion. The company highlighted clinical progress on its VAX-31 vaccine program, including initiation of three Phase 3 trials and completion of enrollment in an infant Phase 2 study, along with a recent $632.5 million equity offering that strengthens its balance sheet.

Key Financial Metrics

EPS
$-5.63

Key Facts

  • Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, down from $3.13 billion in 2024
  • Completed $632.5 million equity offering in February 2026
  • Net loss was $766.6 million for 2025, compared to $463.9 million in 2024
  • Research and development expenses were $794.3 million for 2025, up from $476.6 million in 2024
  • Initiated three Phase 3 trials for VAX-31 (OPUS-1, OPUS-2, OPUS-3)
  • Completed enrollment in VAX-31 infant Phase 2 dose-finding study with 900 infants
  • No revenue or earnings guidance provided

Financial Impact

Increased R&D spending by $317.7 million year-over-year to $794.3 million, resulting in net loss expanding by $302.7 million to $766.6 million

cashnet lossr&d expenses

Risk Factors

  • Clinical trial setbacks could impact valuation
  • Continued significant cash burn from R&D investments
  • No revenue generation expected for several years as company remains pre-commercial

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001649094-26-000005
Document: pcvx-20260224.htm0001649094-26-000005
Document: 0001649094-26-000005-index-headers.html0001649094-26-000005
Document: 0001649094-26-000005-index.html0001649094-26-000005
Document: 0001649094-26-000005.txt0001649094-26-000005

US Market Status

Market Closed · Opens Wed (11h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026